Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study

OBJECTIVE: Lenvatinib was the standard first-line therapy for patients with unresectable HCC. PD-1 blockades demonstrated promising efficacy for patients with previously-treated HCC. Therefore, this study was to investigate the feasibility and tolerability of lenvatinib plus PD-1 blockades for patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Meng, Jia, Jiang-Kun, Xu, Jian, Xue, Huan-Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448352/
https://www.ncbi.nlm.nih.gov/pubmed/36081824
http://dx.doi.org/10.2147/CMAR.S372125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448352/
https://www.ncbi.nlm.nih.gov/pubmed/36081824
http://dx.doi.org/10.2147/CMAR.S372125

Ejemplares similares